NCT05724732 is a EARLY_PHASE1 clinical trial of GT201 in Solid Tumor, sponsored by RenJi Hospital.

Who is sponsoring NCT05724732?

NCT05724732 is sponsored by RenJi Hospital.

What drugs are being tested in NCT05724732?

Interventions in NCT05724732: GT201.

What condition does NCT05724732 study?

NCT05724732 studies Solid Tumor.

Is NCT05724732 still recruiting?

NCT05724732 is currently status unknown. Last updated 13 February 2023.

Last reviewed 2023-02-13 · How we verify

NCT05724732

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Exploratory Clinical Study of Autologous Tumor-infiltrating Lymphocyte Injection (GT201) for Advanced Gynecologic Tumors

Status unknown EARLY_PHASE1 Last updated 13 February 2023

What this trial tests

EARLY_PHASE1 trial testing GT201 in Solid Tumor in 24 participants. Status unknown.

Timeline

1 February 2023

Primary endpoint
1 May 2025

1 May 2025

Quick facts

Lead sponsor	RenJi Hospital
Phase	EARLY_PHASE1
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	24
Start date	1 February 2023
Primary completion	1 May 2025
Estimated completion	1 May 2025
Sites	1 location across China

Drugs / interventions tested

GT201 — full drug profile →

Conditions studied

Solid Tumor — all drugs for Solid Tumor →

Sponsor

RenJi Hospital

Who can join

Adults 18 to 70, female only, with Solid Tumor. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study is a single-center, single-arm phase I clinical trial. A total of 24\~26 subjects (20 evaluable cases are expected) from 1 cohort will be enrolled in this study. An "autologous tumor-infiltrating lymphocyte therapy" dosing regimen consisting of lymphodepleting chemotherapy (FC regimen: cyclophosphamide + fludarabine), infusion of autologous tumor-infiltrating lymphocyte injection, and interleukin-2 injection will be used.The study process is divided into: screening period, sampling and production period, clearing and chemotherapy period, treatment and observation period, and follow-up period

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Recent clinical researches and technological development in TIL therapy.
Matsueda S, Chen L, Li H, Yao H, et al · · 2024 · cited 23× · PMID 39264449 · DOI 10.1007/s00262-024-03793-4
Research progress on tumor-infiltrating lymphocyte therapy for cervical cancer.
Zhang W, Liu YM, Li D, Liu S, et al · · 2025 · cited 4× · PMID 40458394 · DOI 10.3389/fimmu.2025.1524842

Verify or expand the search:

Other trials of GT201

Trials testing the same drug.

NCT06144671 — GT201 Injection For The Treatment Of Advanced Solid Tumors · Phase 1, PHASE2 · recruiting
NCT05729399 — Clinical Study of Autologous Tumor-infiltrating Lymphocyte Injection (GT201) for Advanced Solid Tumors · Phase 1, PHASE2 · recruiting

Other recruiting trials for Solid Tumor

Currently open trials in the same condition.

NCT07489378 — NCI Childhood Cancer Data Initiative (CCDI) Led Pediatric, Adolescent, and Young Adult Rare Cancer Registry for Very Rar · recruiting
NCT07487597 — Functionally Enhanced ALPP-Targeted Engineered T Cells in Advanced Solid Tumors · EARLY_PHASE1 · recruiting
NCT07382544 — Phase 1b Trial of BMS-986504 in Combination With Olaparib in Patients With MTAP Loss · Phase 1 · recruiting
NCT07466160 — A Phase Ib/II Study of 7MW3711 Combined With JS207 in Advanced Solid Tumors · Phase 1, PHASE2 · recruiting
NCT07450560 — Research on Real-time Proton Therapy Guidance Through Monitoring Proton Range Using All-digital PET · active not recruiting

Other RenJi Hospital trials

Trials by the same sponsor.

NCT07584733 — Biomarker-Enriched Kidney-Preserving Strategy With Disitamab Vedotin Plus Tislelizumab in HER2-Positive High-Risk Upper · Phase 2 · not yet recruiting
NCT07537725 — EEG-TMS for Postoperative Delirium After Cardiac Surgery · NA · not yet recruiting
NCT07527936 — A Study of BEN301 Injection in theTreatment of Autoimmune Diseases · EARLY_PHASE1 · not yet recruiting
NCT07343076 — Efficacy of Immediate Versus Staged Complete Revascularization in Patients With NSTE-ACS and Multivessel Disease (FUTURE · NA · not yet recruiting
NCT07449793 — Biochemical Response and Clinical Outcomes in Patients With PBC · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05724732 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by RenJi Hospital
Last refreshed: 13 February 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05724732.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing